Retatrutide vs VK2735
How Retatrutide and VK2735 compare — what each is, how strong the human evidence is for each, doses reported in research, the key risks, and 2026 US legal status. No universal winner.
Retatrutide and VK2735 come up together when people are weighing similar options. Here's the honest side-by-side: what each is, how strong the human evidence is for each, the doses reported in research, the risks, and where each stands with the FDA as of 2026. There's no universal winner — scroll to the by-goal picks for which one fits which goal.
Retatrutide vs VK2735, point by point
Every dimension side by side — the honest differences, not a scoreboard.
| Dimension | Retatrutide | VK2735 |
|---|---|---|
| What it is | Synthetic triple-agonist peptide (one molecule that switches on the GIP, GLP-1, and glucagon receptors) | Investigational dual GIP/GLP-1 receptor agonist peptide |
| Class / category | Incretin / metabolic | Incretin / metabolic |
| Evidence tier | Human RCT · Helped | Human RCT · Helped |
| Studied / approved for | Obesity / weight loss; Type 2 diabetes; MASLD (fatty liver disease); Obesity-related cardiovascular & kidney outcomes; Knee osteoarthritis pain in people with obesity or overweight; Obstructive sleep apnea in people with obesity | Weight management in adults with obesity or overweight; Weight management in adults with type 2 diabetes and obesity or overweight |
| US regulatory status (2026) | investigational (as of Jul 2026) | investigational (as of Jul 2026) |
| Doses reported in research | No established study doses | No established study doses |
| Registered trials (ClinicalTrials.gov) | 33 | No data |
| Banned in sport (WADA) | Yes — on the WADA prohibited list | Yes — on the WADA prohibited list |
| Key risks | Retatrutide has more human safety data than most compounds on this site, because it has reported phase 3 trials — but it is still investigational and its long-term profile is being filled in during ongoing phase 3 studies. The most common side effects are gastrointestinal (nausea, vomiting, diarrhea, constipation), dose-related and usually heaviest early on. Like other incretin drugs, it carries a rodent thyroid C-cell tumor signal whose human relevance is unsettled, and it raises heart rate in a dose-dependent way. | VK2735 has short-term human safety data, not an approved drug label or a long-term safety record. Gastrointestinal events such as nausea, constipation, vomiting, and diarrhea were common in Phase 2. Higher doses caused more treatment stops in the injection study. Gray-market products add separate uncertainty about identity, dose accuracy, storage, purity, and sterility. |
- Evidence tier: A tier reflects how human the evidence is, not a promise the compound works.
Which one fits which goal?
There's no universal winner here — the honest answer depends on what you're after. These picks are framed by goal, and each says why.
Which one fits your goal
These two overlap enough that the honest call comes down to your specific goal and how much human evidence you want before trying something. Compare the differences in the table above — there's no universal winner here.
References
- 1.Retatrutide — indexed research (PubMed, National Library of Medicine)
- 2.Retatrutide — registered clinical studies (ClinicalTrials.gov)
- 3.Retatrutide phase 2 obesity trial record (ClinicalTrials.gov, NCT04881760)
- 4.TRIUMPH-Outcomes phase 3 cardiovascular & kidney trial (ClinicalTrials.gov, NCT06383390)
- 5.TRIUMPH-1 phase 3 obesity results (Eli Lilly)
- 6.TRANSCEND-T2D-1 phase 3 diabetes results (Eli Lilly)